BioVectra Revenue and Competitors

BioVectra manufactures ingredients for global pharmaceutical and biotechnology clients offering therapeutics used in the treatment of cancer, kidney disease, cardio-vascular disease, multiple sclerosis, and many other serious diseases. With over 40 years experience, our company is proficient in synthetic organic chemistry, fermentation of chemical and biologic molecules, downstream processing, MPEG production and conjugation chemistry. We have submitted 10 product filings, including ANDA, DMF, VMF, and CMC section preparations for both the U.S. FDA and Health Canada. These filings have been made for both synthetic and biologic molecules, and include a human injectable API, as well as a final drug product. We operate from three, FDA-inspected facilities in Prince Edward Island, Canada, with the capacity to produce commercial-scale active pharmaceutical ingredients. Our operations are currently expanding to a fourth plant in Nova Scotia, offering further capacity for fermentation and small-scale complex chemistry. BioVectra has the experience and flexibility to work with small to large pharmaceutical, biotechnology, generic, and early stage companies. Our specialized capabilities, quality history, long-term customer relationships and culture of versatility all contribute to achieving our customers unique and diverse requirements.

keywords:Biotechnology,Healthcare,Pharmaceuticals